

Special Issue

Oral Squamous Cell Carcinoma: Molecular Signaling Pathways and Novel Biomarkers

Message from the Guest Editor

Oral squamous cell carcinoma (OSCC) is the most common malignant neoplasm of the oral cavity, posing significant challenges in terms of diagnosis, treatment, and prognosis. Understanding the intricate molecular mechanisms and identifying reliable biomarkers is crucial for improved early detection, diagnosis, and targeted therapy.

The scope of this Special Issue includes the exploration of molecular signaling pathways involved in OSCC development, progression, and metastasis. It will unfold the dysregulation of key signaling pathways, including but not limited to the Notch, Wnt/ β -catenin, PI3K/AKT, MAPK, and NF- κ B pathways. Emphasis will be placed on elucidating the cross-talk between these pathways and their impact on tumour growth, invasion, angiogenesis, metastasis, and immune response modulation.

Additionally, contributions may include studies on genetic, epigenetic, transcriptomic, proteomic, and metabolomic biomarkers. By bringing together the latest advancements in this field, this Special Issue aims to contribute to the understanding of OSCC pathogenesis and innovative treatment strategies for improved patient outcomes.

Guest Editor

Dr. Sadhna Aggarwal

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (31 March 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/178124

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).